What is LabGenius?
Headquartered in London, LabGenius operates at the intersection of computer science, synthetic biology, and robotic automation. Its core asset, the EVA platform, represents a paradigm shift in how proteins are engineered, moving away from traditional, manual laboratory processes toward a data-driven, iterative discovery model. By synthesizing expertise in software engineering, data science, and molecular biology, the company is effectively shortening the development cycle for novel therapeutics. The firm's market position is defined by its ability to solve complex biological challenges through computational precision, making it a critical partner for enterprise-level pharmaceutical and biotech organizations seeking to accelerate their R&D pipelines.
How much funding has LabGenius raised?
LabGenius has raised a total of $73.2M across 3 funding rounds:
Angel/Seed
$3.7M
Series A
$25M
Series B
$44.5M
Angel/Seed (2017): $3.7M with participation from Berggruen Holdings, Kindred Capital, Acequia Capital, Beast Ventures, and System.One.
Series A (2020): $25M led by Chris Gibson, The Obvious, Air Street Capital, Atomico, Patrick Pichette, Felicis Ventures, Lux Capital, and Inovia Capital
Series B (2024): $44.5M supported by Octopus Ventures, M/ventures, and LG
Key Investors in LabGenius
Octopus Ventures
Octopus Ventures is a founder-focused venture capital firm backing mission-driven companies across software, climate, health, and financial technology, offering long-term capital and strategic guidance.
M/ventures
M/ventures is the investment arm of M/CAPITAL PARTNERS, providing smart money and operational support to promising startups across diverse industries.
LG
LG Corp is a global holding company managing a vast portfolio of subsidiaries in electronics, chemicals, and telecommunications, providing significant industrial backing to innovative ventures.
What's next for LabGenius?
With the successful closure of this major strategic investment, LabGenius is poised to accelerate the deployment of its EVA platform across broader therapeutic applications. The company's strategic roadmap likely involves expanding its internal R&D capacity and deepening its partnerships with global pharmaceutical entities. As the biotech industry increasingly pivots toward AI-native discovery, LabGenius is well-positioned to capitalize on the demand for high-throughput, automated protein engineering. Future growth will likely focus on scaling its robotic infrastructure and enhancing its machine learning models to address increasingly complex protein structures, thereby solidifying its competitive advantage in the global life sciences market.
See full LabGenius company page
